Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 214

1.
2.

The interaction between checkpoint kinase 1 (Chk1) and the mini-chromosome maintenance (MCM) complex is required for DNA damage-induced Chk1 phosphorylation.

Han X, Aslanian A, Fu K, Tsuji T, Zhang Y.

J Biol Chem. 2014 Jul 21. pii: jbc.M114.575035. [Epub ahead of print]

PMID:
25049228
[PubMed - as supplied by publisher]
Free Article
3.

Lenalidomide inhibits the proliferation of chronic lymphocytic leukemia cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53.

Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, Cathers B, Schwaederlé M, Cui B, Lopez-Girona A, Messmer D, Kipps TJ.

Blood. 2014 Jul 2. pii: blood-2014-03-559591. [Epub ahead of print]

PMID:
24990888
[PubMed - as supplied by publisher]
4.

The impact of co-administration of ketoconazole and rifampin on the pharmacokinetics of apremilast in healthy volunteers.

Liu Y, Zhou S, Wan Y, Wu A, Palmisano M.

Br J Clin Pharmacol. 2014 Jun 24. doi: 10.1111/bcp.12448. [Epub ahead of print]

PMID:
24962564
[PubMed - as supplied by publisher]
5.

Thymine DNA Glycosylase is a CRL4Cdt2 Substrate.

Slenn TJ, Morris B, Havens CG, Freeman RM Jr, Takahashi TS, Walter JC.

J Biol Chem. 2014 Jun 19. pii: jbc.M114.574194. [Epub ahead of print]

PMID:
24947512
[PubMed - as supplied by publisher]
Free Article
6.

A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.

Rini B, Redman B, Garcia JA, Burris HA 3rd, Li S, Fandi A, Beck R, Jungnelius U, Infante JR.

Ann Oncol. 2014 Jun 8. pii: mdu212. [Epub ahead of print]

PMID:
24914044
[PubMed - as supplied by publisher]
7.

The impact of Nucleofection® on the activation state of primary human CD4 T cells.

Zhang M, Ma Z, Selliah N, Weiss G, Genin A, Finkel TH, Cron RQ.

J Immunol Methods. 2014 Jun;408:123-31. doi: 10.1016/j.jim.2014.05.014. Epub 2014 Jun 5.

PMID:
24910411
[PubMed - in process]
8.
9.

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.

Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, Man HW, Muller GW, Stirling DI, Chopra R.

Cell Signal. 2014 Sep;26(9):2016-29. doi: 10.1016/j.cellsig.2014.05.014. Epub 2014 May 29.

PMID:
24882690
[PubMed - in process]
Free Article
10.

FDA Approval: Ado-trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer.

Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, Weinberg WC, Chi B, Candau-Chacon R, Hughes P, Russell AM, Pope Miksinski S, Chen XH, McGuinn WD, Palmby T, Schrieber SJ, Liu Q, Wang J, Song P, Mehrotra N, Skarupa L, Clouse K, Al-Hakim A, Sridhara R, Ibrahim A, Justice R, Pazdur R, Cortazar P.

Clin Cancer Res. 2014 May 30. pii: clincanres.0012.2014. [Epub ahead of print]

PMID:
24879797
[PubMed - as supplied by publisher]
11.

Embryo-fetal exposure and developmental outcome of thalidomide following oral and intravaginal administration to pregnant rabbits.

Hui JY, Hoffmann M, Kumar G.

Reprod Toxicol. 2014 May 22. pii: S0890-6238(14)00078-1. doi: 10.1016/j.reprotox.2014.05.002. [Epub ahead of print]

PMID:
24859269
[PubMed - as supplied by publisher]
12.

Modeling and simulation to probe the pharmacokinetic disposition of pomalidomide R- and s-enantiomers.

Li Y, Zhou S, Hoffmann M, Kumar G, Palmisano M.

J Pharmacol Exp Ther. 2014 Aug;350(2):265-72. doi: 10.1124/jpet.114.215251. Epub 2014 May 15.

PMID:
24833703
[PubMed - in process]
Free Article
13.

Introduction to the HESI DART Drugs in Semen Consortium.

Chen CL, Beyer BK, Breslin WJ, DeLise AM, Hui JY, Moffat GJ, Thompson KE.

Reprod Toxicol. 2014 May 4. pii: S0890-6238(14)00064-1. doi: 10.1016/j.reprotox.2014.04.007. [Epub ahead of print] No abstract available.

PMID:
24803405
[PubMed - as supplied by publisher]
14.

Quantification of XRCC and DNA-PK proteins in cancer cell lines and human tumors by LC-MS/MS.

Myers MV, Maxwell SE, Wang X.

Bioanalysis. 2014 May 2. [Epub ahead of print]

PMID:
24785829
[PubMed - as supplied by publisher]
Free Article
15.

In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing.

Tjin Tham Sjin R, Lee K, Walter AO, Dubrovskiy A, Sheets M, Martin TS, Labenski MT, Zhu Z, Tester R, Karp R, Medikonda A, Chaturvedi P, Ren Y, Haringsma H, Etter J, Raponi M, Simmons AD, Harding TC, Niu D, Nacht M, Westlin WF, Petter RC, Allen A, Singh J.

Mol Cancer Ther. 2014 Jun;13(6):1468-79. doi: 10.1158/1535-7163.MCT-13-0966. Epub 2014 Apr 10.

PMID:
24723450
[PubMed - in process]
16.

Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel.

Chen N, Li Y, Ye Y, Palmisano M, Chopra R, Zhou S.

J Clin Pharmacol. 2014 Apr 3. doi: 10.1002/jcph.304. [Epub ahead of print]

PMID:
24719309
[PubMed - as supplied by publisher]
17.

TET2 overexpression in chronic lymphocytic leukemia is unrelated to the presence of TET2 variations.

Hernández-Sánchez M, Rodríguez AE, Kohlmann A, Benito R, García JL, Risueño A, Fermiñán E, De Las Rivas J, González M, Hernández-Rivas JM.

Biomed Res Int. 2014;2014:814294. doi: 10.1155/2014/814294. Epub 2014 Feb 18.

PMID:
24693539
[PubMed - in process]
Free PMC Article
18.

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti GJ, Kulasekararaj A, Göhring G, Giagounidis A, Selleslag D, Muus P, Sanz G, Mittelman M, Bowen D, Porwit A, Fu T, Backstrom J, Fenaux P, MacBeth KJ, Hellström-Lindberg E.

Haematologica. 2014 Jun;99(6):1041-9. doi: 10.3324/haematol.2013.098103. Epub 2014 Mar 28.

PMID:
24682512
[PubMed - in process]
Free PMC Article
19.

Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.

Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, Davies MV, Alexander MJ, Devine M, Loveday KS, Underwood KW, Grinberg AV, Quisel JD, Chopra R, Pearsall RS, Seehra J, Kumar R.

Nat Med. 2014 Apr;20(4):408-14. doi: 10.1038/nm.3512. Epub 2014 Mar 23.

PMID:
24658078
[PubMed - indexed for MEDLINE]
20.

An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia.

Dussiot M, Maciel TT, Fricot A, Chartier C, Negre O, Veiga J, Grapton D, Paubelle E, Payen E, Beuzard Y, Leboulch P, Ribeil JA, Arlet JB, Coté F, Courtois G, Ginzburg YZ, Daniel TO, Chopra R, Sung V, Hermine O, Moura IC.

Nat Med. 2014 Apr;20(4):398-407. doi: 10.1038/nm.3468. Epub 2014 Mar 23.

PMID:
24658077
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk